Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
diaDexus
Data on coronary artery disease presented at AHA sessions
December 7th, 2004
diaDexus announced findings from two studies that were presented at the American Heart Association (AHA) Scientific Sessions held in New Orleans, Lousianna. The first study confirms that elevated levels of Lp-PLA2 (lipoprotein-associated phospholipase A2) independently predict stable coronary artery disease (CAD). An additional study found that Lp-PLA2, as measured by the diaDexus PLAC Test, is not commonly elevated in response to systemic inflammation and has only modest biological variability. In the first study, "Association between Lipoprotein-Associated Phospholipase A2 and Coronary Artery Disease: Focus on its Relationship with Lipoproteins and...
Source: Cardiovascular Business Week (2004-12-07)
|
